{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:12:31Z","timestamp":1786990351245,"version":"build-2736575974"},"reference-count":168,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.idc.2020.02.006","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T02:01:50Z","timestamp":1589940110000},"page":"311-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Herpesvirus Infections Potentiated by Biologics"],"prefix":"10.1016","volume":"34","author":[{"given":"Dora Y.","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Enriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashrit","family":"Multani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/v10020092","article-title":"Infection and transport of herpes simplex virus type 1 in neurons: role of the cytoskeleton","volume":"10","author":"Miranda-Saksena","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.idc.2020.02.006_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fimmu.2019.00373","article-title":"Mechanisms of immune control of mucosal HSV infection: a guide to rational vaccine design","volume":"10","author":"Truong","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.idc.2020.02.006_bib3","first-page":"1713","article-title":"Herpes simplex virus","volume":"vol. 2","author":"Schiffer","year":"2015"},{"key":"10.1016\/j.idc.2020.02.006_bib4","first-page":"1085","article-title":"Varicella zoster virus infections","volume":"vol. 2","author":"Ho","year":"2016"},{"issue":"suppl_2","key":"10.1016\/j.idc.2020.02.006_bib5","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/infdis\/jiy403","article-title":"Immunobiology of varicella-zoster virus infection","volume":"218","author":"Laing","year":"2018","journal-title":"J\u00a0Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2020.02.006_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/v10080444","article-title":"Molecular determinants and the regulation of human cytomegalovirus latency and reactivation","volume":"10","author":"Collins-McMillen","year":"2018","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/rmv.1862","article-title":"Cytomegalovirus latency and reactivation: recent insights into an age old problem","volume":"26","author":"Dupont","year":"2016","journal-title":"Rev Med Virol"},{"issue":"11","key":"10.1016\/j.idc.2020.02.006_bib8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nri2434","article-title":"Cross-regulation between herpesviruses and the TNF superfamily members","volume":"8","author":"Sedy","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.idc.2020.02.006_bib9","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/ecco-jcc\/jjv149","article-title":"Herpes simplex virus sepsis in a young woman with crohn's disease","volume":"9","author":"Haag","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.idc.2020.02.006_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/1752-1947-2-282","article-title":"Disseminated cutaneous Herpes Simplex Virus-1 in a woman with rheumatoid arthritis receiving infliximab: a case report","volume":"2","author":"Justice","year":"2008","journal-title":"J\u00a0Med Case Rep"},{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3109\/00365548.2013.849816","article-title":"Herpes simplex virus encephalitis during treatment with etanercept","volume":"46","author":"Crusio","year":"2014","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2020.02.006_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcv.2013.10.025","article-title":"Acyclovir-resistant herpes simplex encephalitis in a patient treated with anti-tumor necrosis factor-alpha monoclonal antibodies","volume":"59","author":"Schepers","year":"2014","journal-title":"J\u00a0Clin Virol"},{"issue":"9","key":"10.1016\/j.idc.2020.02.006_bib13","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/rheumatology\/keq110","article-title":"Severe pneumonia by aciclovir-resistant varicella-zoster virus during etanercept therapy","volume":"49","author":"Manzano","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.idc.2020.02.006_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12879-019-3768-y","article-title":"A\u00a0case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab - a new side effect after 15 years of usage","volume":"19","author":"Skuhala","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"21","key":"10.1016\/j.idc.2020.02.006_bib15","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.3748\/wjg.v19.i21.3347","article-title":"Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease","volume":"19","author":"Ma","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.006_bib16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/0009922810380452","article-title":"Disseminated cutaneous varicella zoster virus infections during infliximab therapy for Crohn's disease: case report of two pediatric patients at one institution","volume":"50","author":"Kunz","year":"2011","journal-title":"Clin Pediatr (Phila)"},{"issue":"4","key":"10.1016\/j.idc.2020.02.006_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000232389","article-title":"Disseminated herpes zoster mimicking rheumatoid vasculitis in a rheumatoid arthritis patient on etanercept","volume":"219","author":"Tresch","year":"2009","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.idc.2020.02.006_bib19","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/ard.2009.125658","article-title":"Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists","volume":"69","author":"Garcia-Doval","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3 Pt 1","key":"10.1016\/j.idc.2020.02.006_bib20","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/jid.2011.383","article-title":"Risk of herpes zoster in patients receiving anti-TNF-alpha in the prospective French RATIO registry","volume":"132","author":"Serac","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"issue":"9","key":"10.1016\/j.idc.2020.02.006_bib21","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2020.02.006_bib22","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents)","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2020.02.006_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/DHPS.S28801","article-title":"Clinical use of anti-TNF therapy and increased risk of infections","volume":"5","author":"Ali","year":"2013","journal-title":"Drug Healthc Patient Saf"},{"issue":"10","key":"10.1016\/j.idc.2020.02.006_bib24","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2169\/internalmedicine.49.3188","article-title":"Cytomegalovirus-induced infectious mononucleosis-like syndrome in a rheumatoid arthritis patient treated with methotrexate and infliximab","volume":"49","author":"Shimojima","year":"2010","journal-title":"Intern Med"},{"issue":"9","key":"10.1016\/j.idc.2020.02.006_bib25","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1086\/425123","article-title":"Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis","volume":"39","author":"Haerter","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"18","key":"10.1016\/j.idc.2020.02.006_bib26","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.3748\/wjg.14.2912","article-title":"Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment","volume":"14","author":"Sari","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.idc.2020.02.006_bib27","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1086\/428672","article-title":"Cytomegalovirus hepatitis associated with use of anti-tumor necrosis factor-alpha antibody","volume":"40","author":"Mizuta","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2020.02.006_bib28","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/00042737-200212000-00018","article-title":"Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy","volume":"14","author":"Helbling","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.idc.2020.02.006_bib29","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.idc.2020.02.006_bib30","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s12185-012-1160-4","article-title":"Severe hepatitis associated with varicella zoster virus infection in a patient with diffuse large B cell lymphoma treated with rituximab-CHOP chemotherapy","volume":"96","author":"Okamoto","year":"2012","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.idc.2020.02.006_bib31","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jiac.2014.08.006","article-title":"A\u00a0varicella outbreak in B-cell lymphoma patients receiving rituximab-containing chemotherapy","volume":"20","author":"Okamoto","year":"2014","journal-title":"J\u00a0Infect Chemother"},{"issue":"7","key":"10.1016\/j.idc.2020.02.006_bib32","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","article-title":"Rituximab-related viral infections in lymphoma patients","volume":"48","author":"Aksoy","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"10.1016\/j.idc.2020.02.006_bib33","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.idc.2020.02.006_bib34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s12185-018-2497-0","article-title":"Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial","volume":"108","author":"Ohmachi","year":"2018","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.idc.2020.02.006_bib36","first-page":"2322","article-title":"HSV-2-encephalitis in a patient with multiple sclerosis treated with ocrelizumab","volume":"266","author":"Dudek","year":"2019","journal-title":"J\u00a0Neurol"},{"issue":"13","key":"10.1016\/j.idc.2020.02.006_bib37","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(15)00143-6","article-title":"Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study","volume":"16","author":"van Oers","year":"2015","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.idc.2020.02.006_bib38","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9980","key":"10.1016\/j.idc.2020.02.006_bib39","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.idc.2020.02.006_bib40","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.bbmt.2018.05.026","article-title":"Safety analysis of brentuximab vedotin from the phase III AETHERA trial in hodgkin lymphoma in the post-transplant consolidation setting","volume":"24","author":"Nademanee","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.therap.2018.07.004","article-title":"Adverse reactions related to brentuximab vedotin use: a real-life retrospective study","volume":"74","author":"Clarivet","year":"2019","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib42","doi-asserted-by":"crossref","first-page":"ofx091","DOI":"10.1093\/ofid\/ofx091","article-title":"Cytomegalovirus infection with retinitis after brentuximab vedotin treatment for CD30(+) lymphoma","volume":"4","author":"Tudesq","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2020.02.006_bib43","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.idc.2020.02.006_bib44","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.clml.2018.10.002","article-title":"Cytomegalovirus reactivation in a patient with extensively pretreated multiple myeloma during daratumumab treatment","volume":"19","author":"Frerichs","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.idc.2020.02.006_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13164","article-title":"Severe cytomegalovirus enterocolitis developing following daratumumab exposure in three patients with multiple myeloma","author":"Lavi","year":"2018","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib46","doi-asserted-by":"crossref","first-page":"e0211927","DOI":"10.1371\/journal.pone.0211927","article-title":"Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma","volume":"14","author":"Nahi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.idc.2020.02.006_bib47","unstructured":"Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761036s004lbl.pdf."},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib48","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.idc.2020.02.006_bib49","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.pathol.2017.03.009","article-title":"Idelalisib induced CMV gastrointestinal disease: the need for vigilance with novel therapies","volume":"49","author":"Goldring","year":"2017","journal-title":"Pathology"},{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.idc.2020.02.006_bib51","unstructured":"Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211155s000lbl.pdf."},{"issue":"23","key":"10.1016\/j.idc.2020.02.006_bib52","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.idc.2020.02.006_bib53","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2020.02.006_bib54","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1016\/j.idc.2020.02.006_bib55","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: a review in rheumatoid arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib56","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.006_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/acr.23824","article-title":"Risk of hospitalized infection and initiation of abatacept versus TNF inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study","volume":"72","author":"Chen","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.idc.2020.02.006_bib58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.idc.2020.02.006_bib59","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.ajkd.2016.09.021","article-title":"Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial","volume":"69","author":"Grinyo","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.idc.2020.02.006_bib60","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/ajt.13830","article-title":"Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study","volume":"16","author":"Durrbach","year":"2016","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.idc.2020.02.006_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12704","article-title":"Fatal case of cutaneous-sparing orolaryngeal zoster in a renal transplant recipient","volume":"19","author":"Helou","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.idc.2020.02.006_bib62","article-title":"Cytomegalovirus retinitis with belatacept immunosuppression","author":"Fan","year":"2019","journal-title":"Retin Cases Brief Rep"},{"issue":"1","key":"10.1016\/j.idc.2020.02.006_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","article-title":"Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab\u2217","volume":"132","author":"Thursky","year":"2006","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib64","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ajh.20780","article-title":"Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab","volume":"82","author":"Cheung","year":"2007","journal-title":"Am J Hematol"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2020.02.006_bib65","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib66","article-title":"Alemtuzumab for patients with chronic lymphocytic leukaemia","author":"Skoetz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.idc.2020.02.006_bib67","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419836913","article-title":"Pulsed immune reconstitution therapy in multiple sclerosis","volume":"12","author":"Sorensen","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"9856","key":"10.1016\/j.idc.2020.02.006_bib68","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.idc.2020.02.006_bib69","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.idc.2020.02.006_bib70","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/1352458516688350","article-title":"Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab","volume":"23","author":"Clerico","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.idc.2020.02.006_bib71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.msard.2017.12.009","article-title":"Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment","volume":"20","author":"Barone","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.idc.2020.02.006_bib72","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.msard.2018.09.031","article-title":"Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis","volume":"27","author":"Buonomo","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib73","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.idc.2020.02.006_bib74","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2340\/00015555-3121","article-title":"Eye complications during dupilumab treatment for severe atopic dermatitis","volume":"99","author":"Ivert","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"10.1016\/j.idc.2020.02.006_bib75","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib76","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.alit.2016.11.006","article-title":"Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma","volume":"66","author":"Shimoda","year":"2017","journal-title":"Allergol Int"},{"issue":"13","key":"10.1016\/j.idc.2020.02.006_bib77","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.idc.2020.02.006_bib78","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"issue":"17","key":"10.1016\/j.idc.2020.02.006_bib79","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2020.02.006_bib80","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.idc.2020.02.006_bib81","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.idc.2020.02.006_bib82","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","article-title":"Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma","volume":"5","author":"Murphy","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"10056","key":"10.1016\/j.idc.2020.02.006_bib83","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib84","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/crj.12998","article-title":"Disseminated herpes zoster following treatment with benralizumab","volume":"13","author":"Mishra","year":"2019","journal-title":"Clin Respir J"},{"issue":"1","key":"10.1016\/j.idc.2020.02.006_bib85","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.idc.2020.02.006_bib86","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.idc.2020.02.006_bib87","first-page":"467","article-title":"CMV associated acute liver failure in a patient receiving tocilizumab for systemic lupus erythematosus","volume":"55","author":"Fromhold-Treu","year":"2017","journal-title":"Z\u00a0Gastroenterol"},{"issue":"14","key":"10.1016\/j.idc.2020.02.006_bib88","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2169\/internalmedicine.55.5981","article-title":"Cytomegalovirus reactivation induced acute hepatitis and gastric erosions in a patient with rheumatoid arthritis under treatment with an anti-il-6 receptor antibody, tocilizumab","volume":"55","author":"Komura","year":"2016","journal-title":"Intern Med"},{"issue":"8","key":"10.1016\/j.idc.2020.02.006_bib89","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/rheumatology\/key121","article-title":"Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.idc.2020.02.006_bib90","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib91","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/rheumatology\/kez265","article-title":"Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up","volume":"59","author":"Fleischmann","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib92","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A\u00a0phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"Voorhees","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.idc.2020.02.006_bib93","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejca.2017.09.019","article-title":"Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis","volume":"86","author":"Franklin","year":"2017","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.idc.2020.02.006_bib94","first-page":"212","article-title":"Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab","volume":"38","author":"Uslu","year":"2015","journal-title":"J\u00a0Immunother"},{"issue":"11","key":"10.1016\/j.idc.2020.02.006_bib95","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2020.02.006_bib96","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.idc.2020.02.006_bib97","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.exphem.2008.05.002","article-title":"Dasatinib exerts an immunosuppressive effect on CD8+ T\u00a0cells specific for viral and leukemia antigens","volume":"36","author":"Fei","year":"2008","journal-title":"Exp Hematol"},{"issue":"7211","key":"10.1016\/j.idc.2020.02.006_bib98","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature07209","article-title":"Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection","volume":"455","author":"Soroceanu","year":"2008","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.idc.2020.02.006_bib99","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.bbmt.2018.07.013","article-title":"Repurposing nilotinib for cytomegalovirus infection prophylaxis after allogeneic hematopoietic stem cell transplantation: a single-arm, phase ii trial","volume":"24","author":"Lin","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib100","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.tranon.2015.12.004","article-title":"Dasatinib-induced CMV hepatitis in an immunocompetent patient: a rare complication of a common drug","volume":"9","author":"Davalos","year":"2016","journal-title":"Transl Oncol"},{"key":"10.1016\/j.idc.2020.02.006_bib101","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4137\/CCRep.S25327","article-title":"Cytomegalovirus-induced hemorrhagic colitis in a patient with chronic myeloid leukemia (chronic phase) on dasatinib as an upfront therapy","volume":"8","author":"Yassin","year":"2015","journal-title":"Clin Med Insights Case Rep"},{"issue":"10","key":"10.1016\/j.idc.2020.02.006_bib102","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.bbmt.2016.06.022","article-title":"Dasatinib-induced colitis after allogeneic stem cell transplantation for philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"22","author":"Aldoss","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib103","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s15010-017-1105-1","article-title":"Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature","volume":"46","author":"Knoll","year":"2018","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib104","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/cid\/cix325","article-title":"Dasatinib use and risk of cytomegalovirus reactivation after allogeneic hematopoietic-cell transplantation","volume":"65","author":"Prestes","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2020.02.006_bib105","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.006_bib106","first-page":"e16","article-title":"Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour","volume":"48","author":"Durosinmi","year":"2007","journal-title":"Singapore Med J"},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib107","first-page":"976","article-title":"Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate","volume":"9","author":"Mattiuzzi","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.idc.2020.02.006_bib108","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.idc.2020.02.006_bib109","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.idc.2020.02.006_bib111","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1346-8138.13258","article-title":"Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study","volume":"43","author":"Asahina","year":"2016","journal-title":"J\u00a0Dermatol"},{"issue":"7","key":"10.1016\/j.idc.2020.02.006_bib112","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"10.1016\/j.idc.2020.02.006_bib113","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.idc.2020.02.006_bib114","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib115","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2017.03.023","article-title":"Herpes zoster in psoriasis patients treated with tofacitinib","volume":"77","author":"Winthrop","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.idc.2020.02.006_bib116","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.idc.2020.02.006_bib117","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/ibd\/izy387","article-title":"Using number needed to harm to put the risk of herpes zoster from tofacitinib in perspective","volume":"25","author":"Caldera","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"10093","key":"10.1016\/j.idc.2020.02.006_bib118","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.idc.2020.02.006_bib119","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.idc.2020.02.006_bib120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.006_bib121","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.idc.2020.02.006_bib122","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1600-6143.2012.04127.x","article-title":"Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib123","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1212\/WNL.0b013e31829a3311","article-title":"T-cell response against varicella-zoster virus in fingolimod-treated MS patients","volume":"81","author":"Ricklin","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.idc.2020.02.006_bib124","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jneuroim.2018.12.009","article-title":"The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod","volume":"328","author":"Aramideh Khouy","year":"2019","journal-title":"J\u00a0Neuroimmunol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.006_bib125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol"},{"issue":"23","key":"10.1016\/j.idc.2020.02.006_bib126","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1212\/WNL.0000000000001659","article-title":"Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis","volume":"84","author":"Pfender","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.idc.2020.02.006_bib127","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2020.02.006_bib128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jcv.2015.10.018","article-title":"Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy","volume":"73","author":"Kim","year":"2015","journal-title":"J\u00a0Clin Virol"},{"issue":"24","key":"10.1016\/j.idc.2020.02.006_bib129","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.idc.2020.02.006_bib130","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.idc.2020.02.006_bib131","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.idc.2020.02.006_bib132","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/tid.12162","article-title":"High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network","volume":"16","author":"Marchesi","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.idc.2020.02.006_bib133","doi-asserted-by":"crossref","first-page":"409765","DOI":"10.1155\/2012\/409765","article-title":"New rising infection: human herpesvirus 6 is\u00a0frequent in myeloma patients undergoing autologous stem cell transplantation after induction therapy with bortezomib","volume":"2012","author":"Horowitz","year":"2012","journal-title":"Bone Marrow Res"},{"issue":"1","key":"10.1016\/j.idc.2020.02.006_bib134","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-017-0501-4","article-title":"Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma: China Continuation study","volume":"10","author":"Hou","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"10","key":"10.1016\/j.idc.2020.02.006_bib135","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.idc.2020.02.006_bib136","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.idc.2020.02.006_bib137","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.idc.2020.02.006_bib138","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.idc.2020.02.006_bib139","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1002\/cncr.31680","article-title":"Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial","volume":"124","author":"Dimopoulos","year":"2018","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.idc.2020.02.006_bib140","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.idc.2020.02.006_bib141","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.idc.2020.02.006_bib142","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.idc.2020.02.006_bib143","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12185-017-2270-9","article-title":"Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance","volume":"106","author":"Ishitsuka","year":"2017","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.006_bib144","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2169\/internalmedicine.55.5644","article-title":"Cytomegalovirus pneumonia after anti-CC-chemokine receptor 4 monoclonal antibody (mogamulizumab) therapy in an angioimmunoblastic T-cell lymphoma patient","volume":"55","author":"Ishii","year":"2016","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.idc.2020.02.006_bib145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00277-013-1765-6","article-title":"Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T\u00a0cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies","volume":"93","author":"Ohyama","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.idc.2020.02.006_bib146","first-page":"546","article-title":"Antivirals against Herpes viruses","volume":"vol. 1","author":"Aoki","year":"2015"},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib147","doi-asserted-by":"crossref","first-page":"e13061","DOI":"10.1111\/tid.13061","article-title":"Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis","volume":"21","author":"Wada-Shimosato","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2020.02.006_bib148","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-015-2447-3","article-title":"Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)","volume":"94","author":"Sandherr","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.idc.2020.02.006_bib149","unstructured":"Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf."},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJMoa1301150","article-title":"Helicase-primase inhibitor pritelivir for HSV-2 infection","volume":"370","author":"Wald","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.idc.2020.02.006_bib151","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.2016.18189","article-title":"Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrences: a randomized clinical trial","volume":"316","author":"Wald","year":"2016","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.idc.2020.02.006_bib152","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1346-8138.13948","article-title":"Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study","volume":"44","author":"Kawashima","year":"2017","journal-title":"J\u00a0Dermatol"},{"issue":"3","key":"10.1016\/j.idc.2020.02.006_bib153","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"22","key":"10.1016\/j.idc.2020.02.006_bib154","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.idc.2020.02.006_bib155","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.idc.2020.02.006_bib156","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A\u00a0phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.idc.2020.02.006_bib157","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.idc.2020.02.006_bib158","unstructured":"Available at: https:\/\/idsa.confex.com\/idsa\/2017\/webprogram\/Paper65338.html."},{"issue":"7","key":"10.1016\/j.idc.2020.02.006_bib159","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1060028018758431","article-title":"Shingrix: the new adjuvanted recombinant herpes zoster vaccine","volume":"52","author":"James","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.idc.2020.02.006_bib160","first-page":"1069","article-title":"Cytomegalovirus infection","volume":"vol. 2","author":"Zaia","year":"2016"},{"issue":"4","key":"10.1016\/j.idc.2020.02.006_bib161","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/QCO.0000000000000459","article-title":"Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation","volume":"31","author":"Razonable","year":"2018","journal-title":"Curr Opin Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2020.02.006_bib162","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2020.02.006_bib163","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2020.02.006_bib164","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","article-title":"Efficacy and safety of maribavir dosed at 100\u00a0mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial","volume":"12","author":"Winston","year":"2012","journal-title":"Am J Transplant"},{"issue":"13","key":"10.1016\/j.idc.2020.02.006_bib165","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.idc.2020.02.006_bib166","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2016-11-749721","article-title":"Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant","volume":"129","author":"Hiwarkar","year":"2017","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.idc.2020.02.006_bib167","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-016-0653-5","article-title":"Cytomegalovirus vaccines: current status and future prospects","volume":"76","author":"Anderholm","year":"2016","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.idc.2020.02.006_bib168","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14760584.2018.1526085","article-title":"A\u00a0fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection","volume":"17","author":"Diamond","year":"2018","journal-title":"Expert Rev Vaccines"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:17:51Z","timestamp":1760195871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552020300088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":168,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0891552020300088"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2020.02.006","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Herpesvirus Infections Potentiated by Biologics","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2020.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}